Original Publication Date: 1 July, 2017
Publication / Source: Future Oncology
Authors: Elie El Rassy, Pamela Abdayem & Joseph Kattan
Breast cancer (BC) rates are among the highest in cancer incidence and mortality. Most commonly, these patients are erb2 negative and hormone receptor (HR)-positive and thus, receive hormonal therapy as a cornerstone of their treatment in the advanced setting . The majority of these patients respond to hormonal therapy but primary or secondary resistances may be observed. Several resistance mechanisms have been shown to drive the tumor proliferation, growth, cell cycle and progression via upregulation of alternate signaling including EGFR, PI3K, mTOR and CDK4/6 pathways .